Narrow Band Imaging™ (NBI™) Technology

Clinically proven to reduce the likelihood of disease recurrence in patients with NMIBC by 37%* compared to using white light cystoscopy (WLC) alone.¹

Enhanced cystoscopy is a more powerful way to visualize bladder cancer than using traditional WLC alone.
Just push the button - it’s that simple. No need for dyes, drugs, or logistical delays.

NBI technology is not intended to replace histopathological sampling as a means of diagnosis.

NBI technology enables improved visualization of tumor boundaries to help increase detection and decrease recurrence in patients with Non-Muscle Invasive Bladder Cancer (NMIBC)

Studies have shown that NBI:

Visualized 17% more patients, 24% additional tumors, and 28% additional Carcinoma in Situ (CIS)²
Led to 37%* less likelihood of recurrence over 12-35 months ¹

* Derived from the hazard ratio in the study. Low certainty of evidence due to risk of bias and imprecision.

1 Lai LY, Tafuri SM, Ginier EC, Herrel LA, Dahm P, Maisch P, Lane GI. Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer. Cochrane Database of Systematic Reviews 2022, Issue 4. Art. No.: CD014887. DOI: 10.1002/14651858.CD014887.pub2.

2 Li, K., Lin, T., Fan, X., Duan, Y., & Huang, J. (2013). Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: A systematic review and meta-analysis. International Journal of Urology, 20, 602-609. www.ncbi.nlm.nih.gov/pubmed/23113702

Yes! I want to access published clinical studies and patient education materials.